American Italian Pasta
American Italian Pasta Newswire

American Italian Pasta Newswire

Comprehensive Real-Time News Feed for American Italian Pasta.

Results 1 - 18 of 18 in American Italian Pasta

  1. IntelGenx Appoints Mark Nawacki as Special AdvisorRead the original story w/Photo

    Thursday Jan 28 | Market Wire

    IntelGenx Corp., , today announced that it has further strengthened its organization with the engagement of Mr. Mark Nawacki as a Special Advisor to the Executive team. Mr. Nawacki is currently the President and CEO of Searchlight Pharma Inc., a Canadian-based specialty pharmaceutical company focused on the acquisition and commercialization of innovative and unique healthcare and pharmaceutical products.

    Comment?

  2. IntelGenx Corp. Strengthens Senior Management TeamRead the original story

    Thursday Jan 21 | BioSpace

    IntelGenx Corp. , today announced that it has strengthened its management team with the appointment of Mr. Robert Bechard to the position of Vice President, Corporate Development, the appointment of Ms. Nadine Paiement to Vice President, Research and Development and the appointment of Mr. Edward Miller to the position of Director, Investor Relations and Corporate Communications.

    Comment?

  3. IntelGenx Strengthens Senior Management TeamRead the original story w/Photo

    Friday Jan 22 | Market Wire

    IntelGenx Corp. , today announced that it has strengthened its management team with the appointment of Mr. Robert Bechard to the position of Vice President, Corporate Development, the appointment of Ms. Nadine Paiement to Vice President, Research and Development and the appointment of Mr. Edward Miller to the position of Director, Investor Relations and Corporate Communications.

    Comment?

  4. Progressive Supranuclear Palsy Industry Trend, Growth, Analysis and...Read the original story

    Dec 8, 2015 | Emailwire.com

    Researchmoz added Most up-to-date research on "Progressive Supranuclear Palsy Global Clinical Trials Review, H1, 2015" to its huge collection of research reports. Progressive Supranuclear Palsy Global Clinical Trials Review, H1, 2015" provides data on the Progressive Supranuclear Palsy clinical trial scenario.

    Comment?

  5. Nuvo Research's (NRIFF) CEO John London on Q3 2015 Results - Earnings Call TranscriptRead the original story w/Photo

    Nov 11, 2015 | Seeking Alpha

    Good morning. My name is Jonathan, and I will be your conference operator today.

    Comment?

  6. Nuvo Research Announces Appointment To Its Board Of DirectorsRead the original story

    Nov 2, 2015 | BioSpace

    Ms. Sakhia was most recently the Chief Financial Officer of premier specialty pharmaceutical company, Paladin Labs Inc. , for 14 years. As a senior member of the Paladin management team, Ms.

    Comment?

  7. North American Drug Delivery Technologies Market Worth $102.2 Billion by 2017Read the original story w/Photo

    Oct 28, 2015 | SBWire

    The report "North American Drug Delivery Technologies Market Forecasts to 2017", the North American market was valued at $66.7 billion in 2012 and is poised to reach $102.2 billion by 2017. The U.S. registered a higher market share, valued at $59.3 billion in 2012 and is expected to grow at a high single digit CAGR from 2012 to 2017.

    Comment?

  8. Downgrading Caesarstone On Concerns About Its Capital Expenditure...Read the original story w/Photo

    Jan 1, 2012 | Seeking Alpha

    ... Its reported capex costs are less than increases in its PP&E accounts. Investors should study American Italian Pasta, a company charged by the SEC for committing fraud in 2008 for capitalizing substantial manufacturing costs to its balance sheet to ...

    Comment?

  9. New Market Report: Low Back Pain - Pipeline Review, H1 2015Read the original story w/Photo

    Aug 24, 2015 | PR-inside.com

    Global Markets Direct's, 'Low Back Pain - Pipeline Review, H1 2015', provides an overview of the Low Back Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action , route of administration and molecule type, along with latest updates, and featured news and press releases.

    Comment?

  10. Low Back Pain - Pipeline Review, H1 2015; New Report LaunchedRead the original story w/Photo

    Jul 15, 2015 | SBWire

    Low Back Pain - Pipeline Review, H1 2015 provides an overview of the Low Back Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action , route of administration and molecule type, along with latest updates, and featured news and press releases.

    Comment?

  11. Antibe Therapeutics Inc. Announces Change In CFO Position And Granting Of Employee Stock OptionsRead the original story

    Jul 12, 2015 | BioSpace

    Antibe Therapeutics Inc. today announced that Dr. Michael Bumby has resigned as CFO, effective August 1, 2015. Antibe wishes to thank Dr. Bumby for his efforts in taking the Company public in 2013.

    Comment?

  12. Antibe Therapeutics Announces Change in CFO Position and Granting of Employee Stock OptionsRead the original story

    Jul 13, 2015 | Business Wire

    Antibe wishes to thank Dr. Bumby for his efforts in taking the Company public in 2013. Samira Sakhia has been named the Company's CFO on an interim basis replacing Dr. Bumby.

    Comment?

  13. New Study: Corporate Tax Rate Most Important Single Factor for InvestmentRead the original story w/Photo

    Jul 9, 2015 | Tax Foundation

    Multinational corporations , intergovernmental organizations , and academics know that high levels of corporate taxation serve as a disincentive for foreign direct investment . Companies shift resources toward countries that provide the most business-friendly climate and away from those nations more hostile to investment.

    Comment?

  14. Ariad And Paladin Labs Inc. Announce Commercial Distribution...Read the original story

    Jun 9, 2015 | BioSpace

    CAMBRIDGE, Mass., & MONTREAL-- --ARIAD Pharmaceuticals, Inc. and Paladin Labs Inc., an operating company of Endo International plc , today announced that ARIAD has granted Paladin exclusive rights to distribute Iclusiga in Canada for its newly approved indications. Paladin is focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.

    Comment?

  15. ARIAD and Paladin Announce Commercial Distribution Agreement for...Read the original story w/Photo

    Jun 10, 2015 | Investor's Business Daily

    CAMBRIDGE, Mass., & MONTREAL-- -- ARIAD Pharmaceuticals, Inc. and Paladin Labs Inc., an operating company of Endo International plc , today announced that ARIAD has granted Paladin exclusive rights to distribute Iclusiga in Canada for its newly approved indications. Paladin is focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.

    Comment?

  16. Husch adds new food and agribusiness partnerRead the original story w/Photo

    Jun 1, 2015 | Business Journal

    ... Sprungli AG; the $2.2 billion merger between Applebee's and IHOP; and the $1.2 billion merger between American Italian Pasta and Ralcorp. The firm's team has more than 50 attorneys.

    Comment?

  17. Endo To Purchase Par PharmaceuticalsRead the original story

    May 21, 2015 | Chemical and Engineering News

    In the latest consolidation move in the generics industry, the Irish specialty drug firm Endo will pay $8.1 billion to buy U.S.-based Par Pharmaceutical . Together, Endo and Par will be number five in U.S. generics sales.a Includes some Canadian sales.

    Comment?

  18. Endo To Purchase Par PharmaceuticalRead the original story w/Photo

    May 18, 2015 | Chemical and Engineering News

    Endo , a specialty drug firm based in Ireland, will pay $8.1 billion in cash and stock to acquire the U.S.-based generic drug firm Par Pharmaceutical . The combined business will have about $4.2 billion in annual sales.

    Comment?